User login
Key clinical point: Although Psoriatic Arthritis Impact of Disease questionnaire-12 items (PsAID-12) scores were higher in patients with psoriatic arthritis (PsA) who did vs did not have a treatment escalation, physicians relied more on their assessment of disease activity while making treatment-related decisions.
Major finding: Higher mean PsAID-12 score correlated with higher odds of treatment escalation in patients with PsA (odds ratio [OR] 1.58; P < .0001), whereas physician’s assessment of disease activity had the most significant impact on likelihood of treatment escalation (OR 2.68; P < .0001). Longer disease duration, treatment with nonbiologics, and a higher swollen joint count also increased the odds for treatment escalation.
Study details: Findings are from a cross-sectional analysis (the ASSIST study) that included 503 patients with PsA (age ≥ 18 years), of whom 160 patients underwent treatment escalation.
Disclosures: This study was funded by Amgen, and the National Institute for Health Research Oxford Biomedical Research Centre. Several authors declared receiving grants, honoraria, consultancy fees, or travel support from or having ties with various sources, including Amgen.
Source: Coyle C et al. How do patient reported outcome measures affect treatment intensification and patient satisfaction in the management of psoriatic arthritis? A cross sectional study of 503 patients. Rheumatology (Oxford). 2024 (Jan 8). doi: 10.1093/rheumatology/kead679
Key clinical point: Although Psoriatic Arthritis Impact of Disease questionnaire-12 items (PsAID-12) scores were higher in patients with psoriatic arthritis (PsA) who did vs did not have a treatment escalation, physicians relied more on their assessment of disease activity while making treatment-related decisions.
Major finding: Higher mean PsAID-12 score correlated with higher odds of treatment escalation in patients with PsA (odds ratio [OR] 1.58; P < .0001), whereas physician’s assessment of disease activity had the most significant impact on likelihood of treatment escalation (OR 2.68; P < .0001). Longer disease duration, treatment with nonbiologics, and a higher swollen joint count also increased the odds for treatment escalation.
Study details: Findings are from a cross-sectional analysis (the ASSIST study) that included 503 patients with PsA (age ≥ 18 years), of whom 160 patients underwent treatment escalation.
Disclosures: This study was funded by Amgen, and the National Institute for Health Research Oxford Biomedical Research Centre. Several authors declared receiving grants, honoraria, consultancy fees, or travel support from or having ties with various sources, including Amgen.
Source: Coyle C et al. How do patient reported outcome measures affect treatment intensification and patient satisfaction in the management of psoriatic arthritis? A cross sectional study of 503 patients. Rheumatology (Oxford). 2024 (Jan 8). doi: 10.1093/rheumatology/kead679
Key clinical point: Although Psoriatic Arthritis Impact of Disease questionnaire-12 items (PsAID-12) scores were higher in patients with psoriatic arthritis (PsA) who did vs did not have a treatment escalation, physicians relied more on their assessment of disease activity while making treatment-related decisions.
Major finding: Higher mean PsAID-12 score correlated with higher odds of treatment escalation in patients with PsA (odds ratio [OR] 1.58; P < .0001), whereas physician’s assessment of disease activity had the most significant impact on likelihood of treatment escalation (OR 2.68; P < .0001). Longer disease duration, treatment with nonbiologics, and a higher swollen joint count also increased the odds for treatment escalation.
Study details: Findings are from a cross-sectional analysis (the ASSIST study) that included 503 patients with PsA (age ≥ 18 years), of whom 160 patients underwent treatment escalation.
Disclosures: This study was funded by Amgen, and the National Institute for Health Research Oxford Biomedical Research Centre. Several authors declared receiving grants, honoraria, consultancy fees, or travel support from or having ties with various sources, including Amgen.
Source: Coyle C et al. How do patient reported outcome measures affect treatment intensification and patient satisfaction in the management of psoriatic arthritis? A cross sectional study of 503 patients. Rheumatology (Oxford). 2024 (Jan 8). doi: 10.1093/rheumatology/kead679